Literature DB >> 17548494

Cross-resistance to medical and agricultural azole drugs in yeasts from the oropharynx of human immunodeficiency virus patients and from environmental Bavarian vine grapes.

Frank-Michael C Müller1, Andrea Staudigel, Stefanie Salvenmoser, Antje Tredup, Rudolf Miltenberger, Josef V Herrmann.   

Abstract

Cross-resistance among Candida albicans isolates from the oropharynges of human immunodeficiency virus-infected patients (n = 16) and environmental yeast strains of various species (n = 54) to medical and agricultural azole drugs was observed. Precautions against the unnecessary widespread use of azoles in the environment and human medicine are strongly recommended to prevent patients from acquiring azole-resistant yeasts.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17548494      PMCID： PMC1932500          DOI： 10.1128/AAC.00459-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Candida isolates from neonates: frequency of misidentification and reduced fluconazole susceptibility.

Authors:  J L Rowen; J M Tate; N Nordoff; L Passarell; M R McGinnis
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

2.  Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis.

Authors:  F M Müller; M Weig; J Peter; T J Walsh
Journal:  J Antimicrob Chemother       Date:  2000-08       Impact factor: 5.790

3.  A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals.

Authors:  H Ji; W Zhang; Y Zhou; M Zhang; J Zhu; Y Song; J Lü
Journal:  J Med Chem       Date:  2000-06-29       Impact factor: 7.446

Review 4.  Fluconazole resistance in Candida in patients with AIDS--a therapeutic approach.

Authors:  T T Ng; D W Denning
Journal:  J Infect       Date:  1993-03       Impact factor: 6.072

5.  Once-weekly fluconazole to prevent recurrence of oropharyngeal candidiasis in patients with AIDS and AIDS-related complex: a double-blind placebo-controlled study.

Authors:  C L Leen; E M Dunbar; M E Ellis; B K Mandal
Journal:  J Infect       Date:  1990-07       Impact factor: 6.072

6.  Resistance mechanisms in clinical isolates of Candida albicans.

Authors:  Theodore C White; Scott Holleman; Francis Dy; Laurence F Mirels; David A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles.

Authors:  D A Goff; S L Koletar; W J Buesching; J Barnishan; R J Fass
Journal:  Clin Infect Dis       Date:  1995-01       Impact factor: 9.079

8.  Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection.

Authors:  M Ruhnke; A Eigler; I Tennagen; B Geiseler; E Engelmann; M Trautmann
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

Review 9.  New antifungal agents.

Authors:  Aditya K Gupta; Elizabeth Tomas
Journal:  Dermatol Clin       Date:  2003-07       Impact factor: 3.478

Review 10.  Fungal virulence studies come of age.

Authors:  F C Odds; N A Gow; A J Brown
Journal:  Genome Biol       Date:  2001-03-05       Impact factor: 13.583
  10 in total
  11 in total

1.  Azole-Resilient Biofilms and Non-wild Type C. albicans Among Candida Species Isolated from Agricultural Soils Cultivated with Azole Fungicides: an Environmental Issue?

Authors:  José Júlio Costa Sidrim; Gerlane Luziana de Maria; Manoel de Araújo Neto Paiva; Géssica Dos Santos Araújo; Renan Vasconcelos da Graça-Filho; Jonathas Sales de Oliveira; Jamille Alencar Sales; Waldemiro Aquino Pereira-Neto; Glaucia Morgana de Melo Guedes; Débora de Souza Collares Maia Castelo-Branco; Rossana de Aguiar Cordeiro; Raimunda Sâmia Nogueira Brilhante; Marcos Fábio Gadelha Rocha
Journal:  Microb Ecol       Date:  2021-03-16       Impact factor: 4.552

2.  In vitro susceptibility of the yeast pathogen cryptococcus to fluconazole and other azoles varies with molecular genotype.

Authors:  Hin Siong Chong; Rebecca Dagg; Richard Malik; Sharon Chen; Dee Carter
Journal:  J Clin Microbiol       Date:  2010-09-15       Impact factor: 5.948

3.  Treatment of a clinically relevant plant-pathogenic fungus with an agricultural azole causes cross-resistance to medical azoles and potentiates caspofungin efficacy.

Authors:  Albrecht Serfling; Johannes Wohlrab; Holger B Deising
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

4.  Antifungal Resistance and Virulence Among Candida spp. from Captive Amazonian manatees and West Indian Manatees: Potential Impacts on Animal and Environmental Health.

Authors:  José Júlio Costa Sidrim; Vitor Luz Carvalho; Débora de Souza Collares Maia Castelo-Branco; Raimunda Sâmia Nogueira Brilhante; Gláucia Morgana de Melo Guedes; Giovanna Riello Barbosa; Stella Maris Lazzarini; Daniella Carvalho Ribeiro Oliveira; Ana Carolina Oliveira de Meirelles; Fernanda Löffler Niemeyer Attademo; Augusto Carlos da Bôaviagem Freire; Waldemiro de Aquino Pereira-Neto; Rossana de Aguiar Cordeiro; José Luciano Bezerra Moreira; Marcos Fábio Gadelha Rocha
Journal:  Ecohealth       Date:  2016-01-26       Impact factor: 3.184

5.  Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi.

Authors:  Bryce E Mansfield; Hanna N Oltean; Brian G Oliver; Samantha J Hoot; Sarah E Leyde; Lizbeth Hedstrom; Theodore C White
Journal:  PLoS Pathog       Date:  2010-09-30       Impact factor: 6.823

6.  Comparison of human and soil Candida tropicalis isolates with reduced susceptibility to fluconazole.

Authors:  Yun-Liang Yang; Chih-Chao Lin; Te-Pin Chang; Tsai-Ling Lauderdale; Hui-Ting Chen; Ching-Fu Lee; Chih-Wen Hsieh; Pei-Chen Chen; Hsiu-Jung Lo
Journal:  PLoS One       Date:  2012-04-05       Impact factor: 3.240

7.  Clonal expansion and emergence of environmental multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR₃₄/L98H mutations in the cyp51A gene in India.

Authors:  Anuradha Chowdhary; Shallu Kathuria; Jianping Xu; Cheshta Sharma; Gandhi Sundar; Pradeep Kumar Singh; Shailendra N Gaur; Ferry Hagen; Corné H Klaassen; Jacques F Meis
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

8.  Azole resistance in Candida spp. isolated from Catú Lake, Ceará, Brazil: an efflux-pump-mediated mechanism.

Authors:  Raimunda S N Brilhante; Manoel A N Paiva; Célia M S Sampaio; Débora S C M Castelo-Branco; Carlos E C Teixeira; Lucas P de Alencar; Tereza J P G Bandeira; André J Monteiro; Rossana A Cordeiro; Waldemiro A Pereira-Neto; José J C Sidrim; José L B Moreira; Marcos F G Rocha
Journal:  Braz J Microbiol       Date:  2016-01-27       Impact factor: 2.476

Review 9.  Is the emergence of fungal resistance to medical triazoles related to their use in the agroecosystems? A mini review.

Authors:  Aícha Daniela Ribas E Ribas; Pierri Spolti; Emerson Medeiros Del Ponte; Katarzyna Zawada Donato; Henri Schrekker; Alexandre Meneghello Fuentefria
Journal:  Braz J Microbiol       Date:  2016-07-07       Impact factor: 2.476

10.  Assessing the Risk for Resistance and Elucidating the Genetics of Colletotrichum truncatum That Is Only Sensitive to Some DMI Fungicides.

Authors:  Can Zhang; Yongzhao Diao; Weizhen Wang; Jianjun Hao; Muhammad Imran; Hongxia Duan; Xili Liu
Journal:  Front Microbiol       Date:  2017-09-15       Impact factor: 5.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.